By Fineline Cube 
The Shanghai Biomedicine Merger and Acquisition Fund under SIIC Capital has entered into a share transfer agreement to acquire 135,335,204 shares of MicroPort Scientific Corp. (HKG: 0853) from Otsuka Medical Devices Co., Ltd., a subsidiary of Otsuka Holdings. This transaction positions the Shanghai Biomedicine M&A Fund as a strategic shareholder of MicroPort.
Strategic Investment Objectives
This investment aligns with the Shanghai Biomedicine M&A Fund’s role as a “chain leader” supporter in the biomedicine industry. The fund aims to support MicroPort’s development through multiple initiatives:
- Facilitating the expansion of core businesses and potential strategic mergers and acquisitions to foster continuous innovation and scale growth.
- Unlocking synergistic value to enhance MicroPort’s cluster and competitive advantages.
- Strengthening MicroPort’s role as a “chain leader” to drive the agglomeration of upstream and downstream enterprises in Shanghai, attract high-end talent, and promote breakthroughs in key technologies and core components within the local market.-Fineline Info & Tech